Anti-NCAM1/CD56 Antibody (Lorvotuzumab)
Catalog No.
F2113
Anti-NCAM1/CD56 Antibody (Lorvotuzumab)
Featured Products
Lorvotuzumab is a humanized monoclonal antibody derived from mouse monoclonal antibodies and modified by genetic engineering. Its composition includes the antibody structure of the IgG1 subtype. The mechanism of action of Lorvotuzumab is to inhibit the growth and spread of tumor cells by targeting the CD56 molecule (neural cell adhesion molecule, NCAM) and blocking its signaling pathway. It is mainly used to treat cancers that express CD56, such as small cell lung cancer and multiple myeloma.
Quality Control & DataSheet
- View current batch:
145.5 kDa
Dry ice
339306-30-8
-80°C
2 years
Liquid
1 mg/mL
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
hLorvotuzumab, IMGN901
100 mM Pro 20 mM Arg pH 5.0.
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
NCAM1/CD56
Please avoid freeze-thaw cycles.